AstraZeneca pill halves breast cancer progression risk

AstraZeneca's experimental pill, camizestrant, reduced the risk of breast cancer progression or death by half when used in patients showing early resistance to standard treatments. This finding could revolutionize treatment approaches. The study, presented at a medical conference, used a blood test to identify patients with a common form of breast cancer who were developing resistance to existing therapies. Patients switched to camizestrant experienced significantly delayed disease progression compared to those on standard treatment. The trial involved over 3,000 patients with advanced hormone receptor-positive, HER2-negative breast cancer. Researchers are optimistic about the potential of this approach, which could lead to earlier interventions and improved outcomes for patients.